1st Quarter - Report — GILEAD SCIENCES, INC. for GILEAD SCIENCES INC (2017)

Firm

GILEAD SCIENCES, INC.

Client

GILEAD SCIENCES INC

Income

—

Expenses

$1,050,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

11 issue areas, each in the filer's own words, with who lobbied on it and where.

Indian/Native American Affairs IND

Education related to Hepatitis C in American Indian population.

Lobbyist	Covered position, as disclosed
KACY HUTCHISON New	—
DAVID PULLIAM	—

Contacted: Veterans Affairs, Dept of (VA); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS)

Veterans VET

Education related to Hepatitis C

Lobbyist	Covered position, as disclosed
JOSEPH GROGAN	—
KACY HUTCHISON New	—
DAVID PULLIAM	—

Contacted: Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Veterans Affairs, Dept of (VA)

Copyright/Patent/Trademark CPT

Technology transfer, patent rights and funding, patent reform legislation. Patient Protection and Affordable Care Act implementation. Issues related to pharmaceuticals and intellectual property protection. Intellectual property reform.

Lobbyist	Covered position, as disclosed
JOSEPH GROGAN	—
KACY HUTCHISON New	—
DAVID PULLIAM	—

Contacted: SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA); State, Dept of (DOS); HOUSE OF REPRESENTATIVES

Health Issues HCR

Pending healthcare legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; coverage and reimbursement policy for HCV and HIV portfolio; funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Prison population and hepatitis C.

Lobbyist	Covered position, as disclosed
JOSEPH GROGAN	—
KACY HUTCHISON New	—
DAVID PULLIAM	—

Contacted: HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); SENATE; Centers For Medicare and Medicaid Services (CMS)

Foreign Relations FOR

Issues related to pharmaceuticals, international finance for health services and intellectual property protection.

Lobbyist	Covered position, as disclosed
JOSEPH GROGAN	—
KACY HUTCHISON New	—
DAVID PULLIAM	—

Contacted: SENATE; Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); Health & Human Services, Dept of (HHS)

Medicare/Medicaid MMM

Ryan White Care Act reauthorization; Hepatitis C (HCV) policy; HIV/AIDS research, testing and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs. Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing and other access issues; issues related to coverage and reimbursement of pharmaceuticals; FDA issues and 340B.

Lobbyist	Covered position, as disclosed
JOSEPH GROGAN	—
KACY HUTCHISON New	—
DAVID PULLIAM	—

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); State, Dept of (DOS)

Pharmacy PHA

Coverage of pharmaceuticals, cost-sharing and other access issues; Implementation of Public Law No: 111-148, the Patient Protection and Affordable Care Act; issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid, and Affordable Care Act implementation; FDA issues and 340B.

Lobbyist	Covered position, as disclosed
JOSEPH GROGAN	—
KACY HUTCHISON New	—
DAVID PULLIAM	—

Contacted: State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA); Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Law Enforcement/Crime/Criminal Justice LAW

Education related to Hepatitis C in prison population.

Lobbyist	Covered position, as disclosed
KACY HUTCHISON New	—
DAVID PULLIAM	—

Contacted: State, Dept of (DOS); Veterans Affairs, Dept of (VA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Trade (domestic/foreign) TRD

International trade and protection of intellectual property

Lobbyist	Covered position, as disclosed
KACY HUTCHISON New	—
DAVID PULLIAM	—

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Veterans Affairs, Dept of (VA); Health & Human Services, Dept of (HHS)

Taxation/Internal Revenue Code TAX

Issues related to international and corporate tax reform

Lobbyist	Covered position, as disclosed
KACY HUTCHISON New	—
DAVID PULLIAM	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA)

Budget/Appropriations BUD

Issues related to healthcare funding and cost-savings.

Lobbyist	Covered position, as disclosed
JOSEPH GROGAN	—
KACY HUTCHISON New	—
DAVID PULLIAM	—

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); Veterans Affairs, Dept of (VA); Health & Human Services, Dept of (HHS); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.